PHARMAELA
ActiveSummary
The computed 12-month bankruptcy probability of PHARMAELA is 2.2% (moderate). The 2025 annual accounts show negative equity (-€18,810) and a net result of -€30,599. Its solvency ranks better than 19% of 22,595 sector peers (NACE 47, financial year 2025). The company has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals.
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- PHARMAELA
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Région Wallonne, pour autant que cette décision n’entraîne pas de changement en matière de régime linguistique applicable à la société” (deed in French)
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Avec ou sans limitation, un ou plusieurs administrateurs” (deed in French)
Capital, shares and profit
- Kind of sharesWhich classes of shares exist and what rights each class carries.
- “Nominatives, inscrites dans le registre des actions nominatives avec les mentions requises par le Code des sociétés et des associations” (deed in French)
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- One provision in the deed
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Third Tuesday of June
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- “Modifications statuts, tout temps” (deed in French)
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Présents_statuts, si_aucun_autre_liquidateur_désigné” (deed in French)